文献速递浆细胞疾病

在新诊断的多发性骨髓瘤各年龄段患者中,来那度胺维持治疗基础上加用伏立诺他:来自多中心、开放标签、随机III期临床试验‘Myeloma XI’的结果

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
PubMed 文献 · Br J Haematol · 2022-12-21

Myeloma XI试验评估在来那度胺维持治疗基础上加用组蛋白去乙酰化酶抑制剂伏立诺他能否进一步改善新诊断多发性骨髓瘤患者结局。结果显示,来那度胺-伏立诺他组与来那度胺单药组的中位无进展生存期分别为34个月和40个月(HR 1.18,95%CI 0.96-1.44,p=0.109),中位总生存期分别为不可估计和75个月(HR 0.99,95%CI 0.76-1.29,p=0.929),均无显著差异。联合组耐受性较差,剂量调整更多、维持治疗周期更少、因毒性停药率更高。

要点

  • 来那度胺-伏立诺他组与来那度胺单药组的中位无进展生存期分别为34个月和40个月,无显著差异(HR 1.18,95%CI 0.96-1.44,p=0.109)。
  • 两组中位总生存期分别为不可估计和75个月,无显著差异(HR 0.99,95%CI 0.76-1.29,p=0.929)。
  • 联合组耐受性较差,剂量调整更多、维持治疗周期更少、因毒性停药率更高。

核心结论

  • 该试验未达到主要终点,在来那度胺维持治疗基础上加用伏立诺他无获益。

研究设计与样本

  • Myeloma XI是一项多中心、开放标签、随机III期试验,纳入新诊断的多发性骨髓瘤患者。
  • 纳入分析的患者随机接受来那度胺单药维持治疗(10 mg/天,每28天周期第1-21天)或来那度胺联合伏立诺他维持治疗(伏立诺他300 mg/天,每28天周期第1-7天和第15-21天),治疗持续至不可接受的毒性或疾病进展。

主要发现

  • 来那度胺-伏立诺他组与来那度胺单药组的中位无进展生存期分别为34个月和40个月(HR 1.18,95%CI 0.96-1.44,p=0.109),无显著差异。
  • 来那度胺-伏立诺他组与来那度胺单药组的中位总生存期分别为不可估计和75个月(HR 0.99,95%CI 0.76-1.29,p=0.929),无显著差异。
  • 亚组分析显示结局无统计学显著异质性。
  • 来那度胺-伏立诺他联合方案似乎耐受性较差,与来那度胺单药相比,剂量调整更多、维持治疗周期更少、因毒性停药率更高。

关键数值与推荐

  • 来那度胺单药维持治疗方案:10 mg/天,每28天周期第1-21天。
  • 来那度胺联合伏立诺他维持治疗方案:来那度胺10 mg/天(每28天周期第1-21天)联合伏立诺他300 mg/天(每28天周期第1-7天和第15-21天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The 'Myeloma XI' trial, for newly diagnosed patients, aimed to evaluate whether the addition of the histone deacetylase inhibitor vorinostat to the lenalidomide maintenance backbone could improve outcomes further. Patients included in this analysis were randomised to maintenance therapy with lenalidomide alone (10 mg/day on days 1-21 of each 28-day cycle), or in combination with vorinostat (300 mg/day on day 1-7 and 15-21 of each 28-day cycle) with treatment continuing until unacceptable toxicity or progressive disease. There was no significant difference in median progression-free survival between those receiving lenalidomide-vorinostat or lenalidomide alone, 34 and 40 months respectively (hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.96-1.44, p = 0.109). There was also no significant difference in median OS, not estimable and 75 months respectively (HR 0.99, 95% CI 0.76-1.29, p = 0.929). Subgroup analysis demonstrated no statistically significant heterogeneity in outcomes. Combination lenalidomide-vorinostat appeared to be poorly tolerated with more dose modifications, fewer cycles of maintenance therapy delivered and higher rates of discontinuation due to toxicity than lenalidomide alone. The trial did not meet its primary end-point, there was no benefit from the addition of vorinostat to lenalidomide maintenance.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jenner MW, Pawlyn C, Davies FE, et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial. Br J Haematol. 2022. PMID: 36541152. doi:10.1111/bjh.18600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。